DATOM Record · DTM-2026-0703-2E

GLP-1 weight-loss drugs cause you to lose muscle while you lose weight.

DATOM found 51 findings, from 43 studies, that directly tested this claim. Of those findings, 44 (86%) support the idea that GLP-1 weight-loss drugs cause you to lose muscle while you lose weight; 7 (14%) point the other way. Counting findings treats them as 51 independent tests, and they are not: several come from the same paper, and many share authors, labs and cohorts. Once the evidence is weighted and grouped by how independent it actually is, the honest estimate carries a range rather than a single number, and that range runs from 60.6% to 74.7%. A claim is called Supported only when the bottom of its range clears 55%, and this one does, so the verdict is Supported. The weighted range sits below the headline 86% because many of the agreeing findings come from overlapping groups; it is the range, not the headline count, that the verdict rests on.

Exact claim checked GLP-1 receptor agonist therapy at clinically approved doses reduces skeletal muscle mass during weight loss in overweight and obese adults, as measured by lean body mass or appendicular skeletal muscle mass over a treatment period of 12 to 68 weeks.

Domainclinical medicine

Verdict
Unsupported
Contested
Supported
0%68% weighted · range 60.6–74.7% · Supported100%

Supported means that once the evidence is weighted for how independent it really is, even the bottom of its honest range clears the line for “supported”. It does not mean every study agrees: some of the clear findings point the other way. And it does not mean the question is closed: new independent studies could still move it.

Evidence Grade

Grade A · strong evidence base, narrow range

Is this medical advice? No. This looks at whether current evidence supports one specific claim. It does not cover safety, dosing, or side effects, and it is not a recommendation to use or avoid any medication. Talk to a doctor before making a decision about your health.

DisclosureNot commissioned or sponsored.
Revised21 Oct 2026. Rescored from Contested, Grade B to Supported, Grade A. The earlier verdict had been computed on the findings as labelled before the 4 Aug reclassification; computed on the reclassified findings, the bottom of the weighted range clears 55%. Same evidence base.
Revised4 Aug 2026. The claim was reframed to the loss direction and its findings reclassified against it. Same 102-source evidence base; the earlier evaluation is retained in the record's history.

What the evidence looks like

Of the 51 findings, from 43 studies, that directly tested this claim:

44 support7 against

The knowledge graph · every finding, and how they connect

The studies · a sample of the evidence base, the three that weigh most first

Show the other 11
  • ConditionalBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. S. Heymsfield et al., 2026, n/a. doi.org/10.1038/s41591-026-04204-0
  • ConditionalDionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. Yanying Wang et al., 2025, n/a. doi.org/10.1186/s13098-025-01877-4
  • ConditionalOral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.. Kurt Hong et al., 2026, n/a. doi.org/10.2147/DMSO.S574765
  • ConditionalAdvantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide‐Treated and Pair‐Fed Rats. Suyeun Byun et al., 2025, n/a. doi.org/10.1002/cph4.70083
  • ConditionalEffects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.. Valeria Gutierrez de Piñeres et al., 2026, n/a. doi.org/10.1016/j.diabres.2026.113113
  • ConditionalPreserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.. Fabian Sanchis-Gomar et al., 2025, n/a. doi.org/10.1007/s11886-025-02334-4
  • ConditionalMoving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults. Kieran F. Reid et al., 2025, n/a. doi.org/10.3389/fragi.2025.1640030
  • ConditionalSEMAGLUTIDE AND BODY COMPOSITION: A NARRATIVE REVIEW OF ITS EFFECTS ON LEAN MASS AND STRATEGIES FOR PRESERVATION. Anna Tomasiewicz et al., 2025, n/a. doi.org/10.31435/ijitss.3(47).2025.4067
  • ConditionalThe Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.. Lampros Chrysavgis et al., 2025, n/a. doi.org/10.3390/ijms262412130
  • ConditionalWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. J. Wilding et al., 2022, n/a. doi.org/10.1111/dom.14725
  • ConditionalMuscle health in the modern era of incretin-based therapies.. Giuseppe De Girolamo et al., 2026, n/a. doi.org/10.1111/eci.70155

Every study links to the original. The three highlighted weigh most. Some studies in the list bear on the claim only under certain conditions (tagged Conditional) and sit outside the 51 that directly tested it, which is why the sample and the bar above count different things. The complete evidence base is in the full Confidence Report.

• A dated entry, not a live feed. This record changes when DATOM re-examines the claim and publishes a dated revision; earlier evaluations stay in the record's history. · How DATOM checks a claim

DATOM is the public record of scientific claims, checked independently, updated as evidence changes.